SCHEMBL6776883

SCHEMBL6776883

NN=CNc1cccc(C(=O)NCC(=O)NC(CC(=O)O)c2ccc(F)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 10/20 0.52
ITGAV P06756 9/20 0.52
ITGB1 P05556 6/20 0.52
ITGA5 P08648 6/20 0.52
ITGB5 P18084 2/20 0.52
ITGB6 P18564 2/20 0.52
ITGB8 P26012 2/20 0.52
ITGA8 P53708 2/20 0.52
ITGA2B P08514 2/20 0.49
SLC6A9 P48067 7/20 0.48
GPR139 Q6DWJ6 1/20 0.45
SLC6A5 Q9Y345 4/20 0.44
MDM4 O15151 2/20 0.44
MDM2 Q00987 3/20 0.43
KMT2A Q03164 1/20 0.42
CTSA P10619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6782755 0.92 ITGB3 (0.51) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7833841 0.91 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7348529 0.91 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7834453 0.88 ITGB3 (0.55) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7339653 0.87 GPR139 (0.46) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7337737 0.87 ITGB3 (0.45) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7836882 0.87 ITGB3 (0.48) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7833884 0.87 ITGB3 (0.71) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL612700 0.87 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL7834995 0.87 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed